Pfizer, Inc. (PFE)
NYSE • Healthcare
April 2, 2026 at 20:00 UTC
About Pfizer, Inc.
Pfizer, Inc. is a pharmaceutical company that discovers, develops, and supplies medicines and vaccines used in clinical practice worldwide. The operating model links science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use. Manufacturing and quality systems favor continuity, so once therapies enter practice, supply stays steady. Field teams focus on safety, labeling clarity, and guidance that fits real workflows in hospitals and clinics. Access programs and country teams adapt to local rules while holding to common standards. The goal is simple and long-term: turn evidence into dependable options that clinicians can trust and patients can live with. Within healthcare, Pfizer’s role is to make new treatments feel workable in daily care.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Pfizer, Inc.'s Technical Indicators Summary
Pfizer exhibits a bullish technical profile with price around $28.3 trading above short-, medium- and long-term moving averages, signaling broad upward alignment. Momentum is generally positive—RSI in the low 60s, a high CCI and a positive MACD—although the stochastic is overbought, suggesting near-term caution. ADX below 20 points to limited trend strength, while ATR is low at about $0.63 and OBV indicates strong accumulation. The pivot level is close to the price and Bollinger bands show contained range. Technical takeaway: bullish—broad moving-average support and volume backing despite short-term overbought readings.
| Indicator | Value |
|---|---|
RSI (14) | 61.63 |
Stochastic %K (14, 3, 3) | 88.33 |
CCI (20) | 197.22 |
WPR (14) | -18.61 |
Momentum (10) | 0.91 |
MFI | 58.30 |
MACD Level (12, 26) | 0.33 |
Bollinger Bands | $26.20 - $28.38 |
ATR (14) | $0.63 (2.21%) |
ADX (14) | 18.06 |
OBV | 877,945,800 |
Classic Pivot Point | $28.41 |
Fibonacci Pivot Point | $28.41 |
Exponential Moving Averages | $25.50 - $27.74(5 indicators) |
Simple Moving Averages | $25.46 - $27.53(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
The day concluded on a slightly softer note, with PFE maintaining a small -0.81% downside gap and finishing at about 28.32. Into the close, PFE still showed subdued interest, with volume at 0.53× its norm. PFE slides modestly as Pfizer faces a disability-bias suit, with light volume signaling tepid interest.
Price Change
from $28.33 close
+$0.01
Trading Volume
Below avg (40.8M)
21.4M
vs S&P 500 Today
Moderate Underperformance
-0.34%
52-Week Position
Near highs
94.5%
Updated: April 3, 2026 at 20:03 UTC
Quote Summary
PFE Headlines
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
March 15, 2026
Institutional Moves in Major U.S. Equities
March 12, 2026
Argus Upgrade Highlights Pfizer Pipeline
March 5, 2026
Wall St Mixed as Jobs Data, Oil Hit Sentiment
December 17, 2025